177 related articles for article (PubMed ID: 37802637)
1. Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.
Jons D; Grut V; Bergström T; Zetterberg H; Biström M; Gunnarsson M; Vrethem M; Brenner N; Butt J; Blennow K; Nilsson S; Kockum I; Olsson T; Waterboer T; Sundström P; Andersen O
J Neurol Neurosurg Psychiatry; 2024 Mar; 95(4):325-332. PubMed ID: 37802637
[TBL] [Abstract][Full Text] [Related]
2. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.
Tengvall K; Huang J; Hellström C; Kammer P; Biström M; Ayoglu B; Lima Bomfim I; Stridh P; Butt J; Brenner N; Michel A; Lundberg K; Padyukov L; Lundberg IE; Svenungsson E; Ernberg I; Olafsson S; Dilthey AT; Hillert J; Alfredsson L; Sundström P; Nilsson P; Waterboer T; Olsson T; Kockum I
Proc Natl Acad Sci U S A; 2019 Aug; 116(34):16955-16960. PubMed ID: 31375628
[TBL] [Abstract][Full Text] [Related]
3. Follow-up after infectious mononucleosis in search of serological similarities with presymptomatic multiple sclerosis.
Jons D; Persson Berg L; Sundström P; Haghighi S; Axelsson M; Thulin M; Bergström T; Andersen O
Mult Scler Relat Disord; 2021 Nov; 56():103288. PubMed ID: 34634626
[TBL] [Abstract][Full Text] [Related]
4. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
6. Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis.
Grut V; Biström M; Salzer J; Stridh P; Jons D; Gustafsson R; Fogdell-Hahn A; Huang J; Butt J; Lindam A; Alonso-Magdalena L; Bergström T; Kockum I; Waterboer T; Olsson T; Zetterberg H; Blennow K; Andersen O; Nilsson S; Sundström P
Brain; 2024 Jan; 147(1):177-185. PubMed ID: 37930324
[TBL] [Abstract][Full Text] [Related]
7. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
[TBL] [Abstract][Full Text] [Related]
8. Antibodies from Multiple Sclerosis Brain Identified Epstein-Barr Virus Nuclear Antigen 1 & 2 Epitopes which Are Recognized by Oligoclonal Bands.
Wang Z; Kennedy PG; Dupree C; Wang M; Lee C; Pointon T; Langford TD; Graner MW; Yu X
J Neuroimmune Pharmacol; 2021 Sep; 16(3):567-580. PubMed ID: 32808238
[TBL] [Abstract][Full Text] [Related]
9. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Clinical Utility of Epstein-Barr Virus Antibodies as Biomarkers in Multiple Sclerosis: A Systematic Review.
Bose A; Khalighinejad F; Hoaglin DC; Hemond CC
Mult Scler Relat Disord; 2024 Apr; 84():105410. PubMed ID: 38401201
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus and disease activity in multiple sclerosis.
Buljevac D; van Doornum GJ; Flach HZ; Groen J; Osterhaus AD; Hop W; van Doorn PA; van der Meché FG; Hintzen RQ
J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1377-81. PubMed ID: 16170080
[TBL] [Abstract][Full Text] [Related]
12. Anti-EBNA1 IgG titre is not associated with fatigue in multiple sclerosis patients.
Fleischer M; Schuh H; Bickmann NM; Hagenacker T; Krüger K; Skripuletz T; Fiedler M; Kleinschnitz C; Pul R; Skuljec J
Neurol Neurochir Pol; 2022; 56(3):236-245. PubMed ID: 35726751
[TBL] [Abstract][Full Text] [Related]
13. EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.
Monaco MCG; Soldan SS; Su C; Clauze A; Cooper JF; Patel RJ; Lu F; Hughes RJ; Messick TE; Andrada FC; Ohayon J; Lieberman PM; Jacobson S
Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37562974
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling of EBNA1-host protein interactions in latent and lytic Epstein-Barr virus infections.
Malik-Soni N; Frappier L
J Virol; 2012 Jun; 86(12):6999-7002. PubMed ID: 22496234
[TBL] [Abstract][Full Text] [Related]
15. EBNA1.
Frappier L
Curr Top Microbiol Immunol; 2015; 391():3-34. PubMed ID: 26428370
[TBL] [Abstract][Full Text] [Related]
16. In vivo dynamics of EBNA1-oriP interaction during latent and lytic replication of Epstein-Barr virus.
Daikoku T; Kudoh A; Fujita M; Sugaya Y; Isomura H; Tsurumi T
J Biol Chem; 2004 Dec; 279(52):54817-25. PubMed ID: 15498777
[TBL] [Abstract][Full Text] [Related]
17. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.
Lünemann JD; Jelcić I; Roberts S; Lutterotti A; Tackenberg B; Martin R; Münz C
J Exp Med; 2008 Aug; 205(8):1763-73. PubMed ID: 18663124
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
20. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication.
Malecka KA; Dheekollu J; Deakyne JS; Wiedmer A; Ramirez UD; Lieberman PM; Messick TE
J Virol; 2019 Oct; 93(20):. PubMed ID: 31142669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
